Patents by Inventor Ryu Oshima

Ryu Oshima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEMAFIBRATE AND/OR TOFOGLIFLOZIN FOR USE IN TREATING LIVER DISEASE
    Publication number: 20240277745
    Abstract: Pemafibrate, tofogliflozin, or combinations thereof for use in treating human patients with liver diseases, particularly NASH patients suffering from liver stiffness or liver fibrosis, NASH patients with lobular inflammation, NASH patients with elevated LDL-C, and NASH patients with healthy triglyceride levels.
    Type: Application
    Filed: May 25, 2022
    Publication date: August 22, 2024
    Applicant: KOWA COMPANY, LTD
    Inventors: Noboru KANETA, Ryu OSHIMA, Shona Sanchita PENDSE, Ryohei TANIGAWA
  • MEDICAMENT
    Publication number: 20240207233
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: December 31, 2023
    Publication date: June 27, 2024
    Inventors: Ryu OSHIMA, Masatoshi ITO, Chisato NAGAI
  • Pemafibrate dosing regimens
    Patent number: 11857540
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: January 2, 2024
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Masatoshi Ito, Chisato Nagai
  • Pemafibrate Dosing Regimens
    Publication number: 20230115867
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereitiafter also referred to as pemafiterate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pernafiterate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: December 1, 2022
    Publication date: April 13, 2023
    Inventors: Ryu OSHIMA, Masatoshi ITO, Chisato NAGAI
  • METHODS OF TREATING MIXED DYSLIPIDEMIA AND HYPERTRIGLYCERIDEMIA
    Publication number: 20230092776
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.
    Type: Application
    Filed: August 10, 2022
    Publication date: March 23, 2023
    Inventors: Ryu Oshima, Kazuhito Suehira, Gary Gordon
  • Pemafibrate dosing regimens
    Patent number: 11554110
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: January 17, 2023
    Inventors: Ryu Oshima, Masatoshi Ito, Chisato Nagai
  • Pemafibrate dosing regimens
    Patent number: 11554109
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: January 17, 2023
    Inventors: Ryu Oshima, Masatoshi Ito, Chisato Nagai
  • Pemafibrate Dosing Regimens
    Publication number: 20220296588
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: March 30, 2022
    Publication date: September 22, 2022
    Inventors: Ryu OSHIMA, Masatoshi ITO, Chisato NAGAI
  • Methods of treating mixed dyslipidemia and hypertriglycertdemia
    Patent number: 11446282
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.
    Type: Grant
    Filed: December 25, 2019
    Date of Patent: September 20, 2022
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Kazuhito Suehira, Gary Gordon
  • Pemafibrate Dosing Regimens
    Publication number: 20220257627
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: March 30, 2022
    Publication date: August 18, 2022
    Inventors: Ryu OSHIMA, Masatoshi ITO, Chisato NAGAI
  • Endoscope apparatus, activation method, and video processor for determining an abnormality
    Patent number: 11089950
    Abstract: An endoscope apparatus including a connector included in an endoscope and connected to an endoscope connection portion of a video processor, a fluid feeding apparatus including a tube configured to transmit fluid to the endoscope, a connection detector configured to detect a connection state of the tube with the connector of the endoscope, a control unit configured to detect an ON/OFF state of a power source of the fluid feeding apparatus, determine an abnormality exists when the connection detector detects that the tube is in a disconnected state with the connector of the endoscope and the power source of the fluid feeding apparatus is detected to be in an ON state, and output a notification of the determined abnormality, and a display configured to display the notification of the abnormality outputted by the control unit.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: August 17, 2021
    Assignee: OLYMPUS CORPORATION
    Inventors: Kensuke Miyake, Takashi Saito, Ryu Oshima, Masahiro Katakura, Yugo Koizumi, Mai Ojima
  • Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations
    Publication number: 20210085652
    Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 25, 2021
    Inventors: Ryu Oshima, Gary Gordon
  • Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations
    Publication number: 20210077467
    Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 18, 2021
    Inventors: Ryu Oshima, Gary Gordon
  • Methods of Preventing Occurrence of Cardiovascular Events
    Publication number: 20210069158
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Inventors: Ryu Oshima, Gary Gordon
  • Methods of preventing the occurrence of cardiovascular events
    Patent number: 10869859
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.
    Type: Grant
    Filed: July 30, 2017
    Date of Patent: December 22, 2020
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Gary Gordon
  • Methods of preventing cardiovascular events in residual risk dyslipidemic populations
    Patent number: 10864198
    Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
    Type: Grant
    Filed: July 30, 2017
    Date of Patent: December 15, 2020
    Assignee: Kowa Company, Ltd.
    Inventors: Ryu Oshima, Gary Gordon
  • METHODS OF TREATING MIXED DYSLIPIDEMIA AND HYPERTRIGLYCERIDEMIA
    Publication number: 20200147051
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.
    Type: Application
    Filed: December 25, 2019
    Publication date: May 14, 2020
    Inventors: Ryu Oshima, Kazuhito Suehira, Gary Gordon
  • MEDICAMENT
    Publication number: 20200113873
    Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 16, 2020
    Applicant: KOWA COMPANY, LTD.
    Inventors: Ryu OSHIMA, Masatoshi ITO, Chisato NAGAI
  • ENDOSCOPE APPARATUS, ACTIVATION METHOD OF ENDOSCOPE APPARATUS, AND VIDEO PROCESSOR
    Publication number: 20190269308
    Abstract: An endoscope apparatus including a connector included in an endoscope and connected to an endoscope connection portion of a video processor, a fluid feeding apparatus including a tube configured to transmit fluid to the endoscope, a connection detector configured to detect a connection state of the tube with the connector of the endoscope, a control unit configured to detect an ON/OFF state of a power source of the fluid feeding apparatus, determine an abnormality exists when the connection detector detects that the tube is in a disconnected state with the connector of the endoscope and the power source of the fluid feeding apparatus is detected to be in an ON state, and output a notification of the determined abnormality, and a display configured to display the notification of the abnormality outputted by the control unit.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: OLYMPUS CORPORATION
    Inventors: Kensuke MIYAKE, Takashi SAITO, Ryu OSHIMA, Masahiro KATAKURA, Yugo KOIZUMI, Mai OJIMA
  • Methods of Treatment of Hypertriglyceridemia
    Publication number: 20190224169
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 25, 2019
    Inventors: Ryu Oshima, Kazuhito Suehira, Gary Gordon